Genmab — November 2015
-
Uden at gøre mig klog på medicinudvikling tror ikke det er så nemt nohope, specielt med kræftmidler. Der er vel en grund til at de store blockbustere som f.eks. Avastin kan sidde på markedet så længe uden ''bare'' at blive erstattet af en copycat.
-
Er rimelig sikker på at patentet på Dara er meget omfattende, specielt da det jo netop er så niche ved at være bindende til et specifikt molekyle i kroppen
, CD38. -
http://www.google.com/patents/EP2580243A1?cl=en - The present
invention relates to antibodies directed to human CD38 and to uses of such antibodies, in particular therapeutic uses. -
Interim analysis på CASTOR studiet https://clinicaltrials.gov/ct2/show/NCT02076009?term=Daratumumab+lenalidomide&rank=2
-
http://finance.yahoo.com/news/agenus-acquire-antibody-manufacturing-capability-210000160.html Jeg er så glad fordi jeg er igen er blevet medejer af et antibody manufactory plant
-
Solsen - er der nyheder omkring interim analysen på castor?
-
Spændende. Mon dog ikke at den slags analyser er reserverede for fda? Kan f.eks. Se at imbruvica 1st Line er indsendt, men har ikke offentliggjort resultater
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind